PSYENCE BIOMEDICAL LTD Financials
This page shows PSYENCE BIOMEDICAL LTD (PBMWW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
PSYENCE BIOMEDICAL LTD passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
For every $1 of reported earnings, PSYENCE BIOMEDICAL LTD generates $-3.69 in operating cash flow (-$3.7M OCF vs $1.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
PSYENCE BIOMEDICAL LTD reported $1.0M in net income in fiscal year 2025. This represents an increase of 102.0% from the prior year.
Cash & Balance Sheet
PSYENCE BIOMEDICAL LTD generated -$3.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 26.9% from the prior year.
PSYENCE BIOMEDICAL LTD held $6.1M in cash against $0 in long-term debt as of fiscal year 2025.
PSYENCE BIOMEDICAL LTD had 568,021 shares outstanding in fiscal year 2025. This represents a decrease of 95.8% from the prior year.
Margins & Returns
PSYENCE BIOMEDICAL LTD's ROE was 15.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
PSYENCE BIOMEDICAL LTD invested $10K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 72.5% from the prior year.
PBMWW Income Statement
| Metric | Q2'26 | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q4'22 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$753K | N/A | $141K | N/A | -$310K | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PBMWW Balance Sheet
| Metric | Q2'26 | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q4'22 |
|---|---|---|---|---|---|---|---|
| Total Assets | $12.8M+75.1% | $7.3M+224.7% | $2.3M+99.0% | $1.1M | N/A | $1.6M-13.1% | $1.8M |
| Current Assets | $7.6M+16.3% | $6.6M+192.4% | $2.2M+99.1% | $1.1M | N/A | $1.6M-13.1% | $1.8M |
| Cash & Equivalents | $7.1M+16.5% | $6.1M+217.5% | $1.9M+163.6% | $733K+21.1% | $605K-54.6% | $1.3M-23.9% | $1.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $943K+58.7% | $594K-83.1% | $3.5M-71.0% | $12.1M | N/A | $1.8M+1260.3% | $132K |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | $10.4M | N/A | N/A | N/A |
| Total Equity | $11.9M+76.5% | $6.7M+635.6% | -$1.3M+88.6% | -$11.0M-1016.6% | -$983K-390.2% | -$200K-111.8% | $1.7M |
| Retained Earnings | -$58.4M-3.5% | -$56.4M-3.6% | -$54.5M+5.2% | -$57.5M | N/A | -$6.3M-103.6% | -$3.1M |
PBMWW Cash Flow Statement
| Metric | Q2'26 | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q4'22 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PBMWW Financial Ratios
| Metric | Q2'26 | Q4'25 | Q2'25 | Q4'24 | Q2'24 | Q4'23 | Q4'22 |
|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -6.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -5.9% | N/A | 6.3% | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 0.080.0 | 0.09+2.9 | -2.80-1.8 | -0.95 | N/A | -8.93-9.0 | 0.08 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Frequently Asked Questions
Is PSYENCE BIOMEDICAL LTD profitable?
Yes, PSYENCE BIOMEDICAL LTD (PBMWW) reported a net income of $1.0M in fiscal year 2025.
What is PSYENCE BIOMEDICAL LTD's return on equity (ROE)?
PSYENCE BIOMEDICAL LTD (PBMWW) has a return on equity of 15.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is PSYENCE BIOMEDICAL LTD's free cash flow?
PSYENCE BIOMEDICAL LTD (PBMWW) generated -$3.7M in free cash flow during fiscal year 2025. This represents a -26.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is PSYENCE BIOMEDICAL LTD's operating cash flow?
PSYENCE BIOMEDICAL LTD (PBMWW) generated -$3.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are PSYENCE BIOMEDICAL LTD's total assets?
PSYENCE BIOMEDICAL LTD (PBMWW) had $7.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are PSYENCE BIOMEDICAL LTD's capital expenditures?
PSYENCE BIOMEDICAL LTD (PBMWW) invested $10K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is PSYENCE BIOMEDICAL LTD's debt-to-equity ratio?
PSYENCE BIOMEDICAL LTD (PBMWW) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is PSYENCE BIOMEDICAL LTD's return on assets (ROA)?
PSYENCE BIOMEDICAL LTD (PBMWW) had a return on assets of 13.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is PSYENCE BIOMEDICAL LTD's cash runway?
Based on fiscal year 2025 data, PSYENCE BIOMEDICAL LTD (PBMWW) had $6.1M in cash against an annual operating cash burn of $3.7M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is PSYENCE BIOMEDICAL LTD's Piotroski F-Score?
PSYENCE BIOMEDICAL LTD (PBMWW) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are PSYENCE BIOMEDICAL LTD's earnings high quality?
PSYENCE BIOMEDICAL LTD (PBMWW) has an earnings quality ratio of -3.69x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.